A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not ...

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a treatment for depression. A clinic in Denver is looking to help those ...

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

How can you make therapy work best for you? Here are a few tips. And a new study offers more evidence that teens are in trouble.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...